Patients with depression benefit from taking venlafaxine and duloxetine, two drugs belonging to the selective serotonin and norepinephrine reuptake inhibitor drug class. This is the conclusion of a report published by German researchers. Clinical comparisons with a sham drug (placebo) show that patients respond better to the therapy, suffering less from the symptoms of depression.